| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 143 | 2023 | 997 | 14.040 |
Why?
|
| Female | 154 | 2023 | 16402 | 2.050 |
Why?
|
| Anti-HIV Agents | 17 | 2023 | 173 | 1.970 |
Why?
|
| Depression | 16 | 2023 | 472 | 1.810 |
Why?
|
| Antiretroviral Therapy, Highly Active | 18 | 2018 | 146 | 1.670 |
Why?
|
| Vaginosis, Bacterial | 6 | 2021 | 31 | 1.660 |
Why?
|
| Humans | 163 | 2023 | 29801 | 1.590 |
Why?
|
| Adult | 101 | 2023 | 8730 | 1.460 |
Why?
|
| Papillomavirus Infections | 12 | 2016 | 37 | 1.450 |
Why?
|
| Middle Aged | 91 | 2023 | 9952 | 1.450 |
Why?
|
| Gastrointestinal Microbiome | 8 | 2023 | 180 | 1.380 |
Why?
|
| Sex Offenses | 6 | 2022 | 27 | 1.130 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2015 | 51 | 1.120 |
Why?
|
| Cross-Sectional Studies | 32 | 2023 | 970 | 1.080 |
Why?
|
| Substance-Related Disorders | 13 | 2022 | 104 | 1.070 |
Why?
|
| Cohort Studies | 37 | 2022 | 1952 | 0.950 |
Why?
|
| Coinfection | 3 | 2021 | 29 | 0.920 |
Why?
|
| Stress, Psychological | 6 | 2020 | 249 | 0.910 |
Why?
|
| HIV Seropositivity | 12 | 2021 | 95 | 0.880 |
Why?
|
| Prospective Studies | 35 | 2022 | 1821 | 0.870 |
Why?
|
| Anti-Retroviral Agents | 10 | 2023 | 52 | 0.850 |
Why?
|
| Papillomaviridae | 8 | 2016 | 29 | 0.850 |
Why?
|
| Viral Load | 18 | 2022 | 208 | 0.840 |
Why?
|
| Accidental Falls | 7 | 2022 | 117 | 0.820 |
Why?
|
| Risk Factors | 33 | 2022 | 2465 | 0.780 |
Why?
|
| CD4 Lymphocyte Count | 17 | 2021 | 157 | 0.780 |
Why?
|
| HIV Integrase Inhibitors | 4 | 2022 | 6 | 0.770 |
Why?
|
| Quality of Life | 6 | 2022 | 676 | 0.770 |
Why?
|
| Hepatitis C | 2 | 2021 | 66 | 0.770 |
Why?
|
| United States | 38 | 2022 | 2344 | 0.750 |
Why?
|
| Atherosclerosis | 4 | 2023 | 75 | 0.740 |
Why?
|
| Prevalence | 19 | 2021 | 494 | 0.720 |
Why?
|
| Hydrocortisone | 5 | 2022 | 43 | 0.700 |
Why?
|
| Longitudinal Studies | 27 | 2022 | 1462 | 0.690 |
Why?
|
| Mouth Diseases | 6 | 2016 | 9 | 0.640 |
Why?
|
| Carotid Stenosis | 3 | 2023 | 22 | 0.640 |
Why?
|
| Fractures, Avulsion | 1 | 2018 | 3 | 0.640 |
Why?
|
| Tennis | 1 | 2018 | 2 | 0.640 |
Why?
|
| Genitalia, Female | 1 | 2018 | 29 | 0.620 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 97 | 0.610 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2012 | 194 | 0.610 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 102 | 0.610 |
Why?
|
| Athletic Injuries | 4 | 2015 | 180 | 0.610 |
Why?
|
| Carotid Artery Diseases | 3 | 2023 | 44 | 0.590 |
Why?
|
| Pain | 2 | 2019 | 396 | 0.580 |
Why?
|
| Vagina | 4 | 2021 | 49 | 0.570 |
Why?
|
| Surveys and Questionnaires | 19 | 2020 | 1186 | 0.560 |
Why?
|
| Sexual Partners | 7 | 2022 | 16 | 0.560 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 190 | 0.550 |
Why?
|
| Frailty | 3 | 2022 | 39 | 0.540 |
Why?
|
| HIV-1 | 9 | 2021 | 451 | 0.530 |
Why?
|
| Body Mass Index | 7 | 2023 | 425 | 0.530 |
Why?
|
| Patient Compliance | 8 | 2013 | 165 | 0.530 |
Why?
|
| Cytokines | 5 | 2022 | 350 | 0.520 |
Why?
|
| Cognition | 12 | 2023 | 1314 | 0.510 |
Why?
|
| Young Adult | 18 | 2020 | 1966 | 0.510 |
Why?
|
| Menopause | 6 | 2023 | 135 | 0.490 |
Why?
|
| Case-Control Studies | 12 | 2022 | 640 | 0.470 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 382 | 0.460 |
Why?
|
| Risk Assessment | 6 | 2020 | 683 | 0.460 |
Why?
|
| HIV | 9 | 2023 | 92 | 0.460 |
Why?
|
| Prefrontal Cortex | 4 | 2016 | 152 | 0.450 |
Why?
|
| Cognitive Dysfunction | 5 | 2023 | 969 | 0.450 |
Why?
|
| Verbal Learning | 5 | 2017 | 43 | 0.450 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 34 | 0.440 |
Why?
|
| Biomarkers | 9 | 2023 | 704 | 0.440 |
Why?
|
| Aged | 25 | 2022 | 9618 | 0.440 |
Why?
|
| Neuropsychological Tests | 16 | 2022 | 1270 | 0.430 |
Why?
|
| Medication Adherence | 8 | 2019 | 79 | 0.430 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2023 | 25 | 0.420 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2016 | 23 | 0.410 |
Why?
|
| Sex Factors | 7 | 2020 | 497 | 0.410 |
Why?
|
| Parents | 1 | 2013 | 106 | 0.400 |
Why?
|
| Sexual Behavior | 7 | 2022 | 67 | 0.400 |
Why?
|
| Human papillomavirus 16 | 3 | 2016 | 8 | 0.390 |
Why?
|
| Comorbidity | 11 | 2020 | 504 | 0.380 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 22 | 0.370 |
Why?
|
| Women's Health | 6 | 2018 | 247 | 0.370 |
Why?
|
| Smoking Cessation | 3 | 2020 | 50 | 0.370 |
Why?
|
| Cervix Uteri | 3 | 2018 | 40 | 0.360 |
Why?
|
| Vitamin D Deficiency | 3 | 2018 | 10 | 0.360 |
Why?
|
| Microbiota | 3 | 2016 | 105 | 0.350 |
Why?
|
| Cognition Disorders | 4 | 2020 | 1032 | 0.340 |
Why?
|
| Memory | 4 | 2015 | 323 | 0.340 |
Why?
|
| Anxiety | 2 | 2022 | 157 | 0.340 |
Why?
|
| Smoking | 4 | 2017 | 194 | 0.330 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 180 | 0.330 |
Why?
|
| Complementary Therapies | 4 | 2010 | 14 | 0.330 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 106 | 0.330 |
Why?
|
| Violence | 4 | 2022 | 39 | 0.330 |
Why?
|
| Gender-Based Violence | 2 | 2020 | 2 | 0.330 |
Why?
|
| Male | 25 | 2023 | 15844 | 0.320 |
Why?
|
| Chronic Pain | 2 | 2022 | 112 | 0.320 |
Why?
|
| Logistic Models | 12 | 2019 | 410 | 0.320 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 411 | 0.320 |
Why?
|
| Motor Activity | 2 | 2013 | 372 | 0.310 |
Why?
|
| Alcohol Drinking | 3 | 2016 | 77 | 0.310 |
Why?
|
| Diet | 3 | 2021 | 172 | 0.310 |
Why?
|
| Inflammation | 5 | 2023 | 347 | 0.300 |
Why?
|
| Chicago | 11 | 2020 | 867 | 0.300 |
Why?
|
| Adolescent | 13 | 2021 | 2331 | 0.300 |
Why?
|
| Sleep | 4 | 2023 | 318 | 0.290 |
Why?
|
| Fractures, Stress | 1 | 2007 | 22 | 0.290 |
Why?
|
| Bone Density | 3 | 2022 | 151 | 0.280 |
Why?
|
| HIV Seronegativity | 8 | 2018 | 43 | 0.280 |
Why?
|
| Deafness | 1 | 2006 | 16 | 0.280 |
Why?
|
| Sports | 1 | 2006 | 37 | 0.270 |
Why?
|
| Disclosure | 2 | 2020 | 16 | 0.270 |
Why?
|
| Athletes | 2 | 2018 | 76 | 0.270 |
Why?
|
| Follow-Up Studies | 12 | 2022 | 1859 | 0.270 |
Why?
|
| Resilience, Psychological | 3 | 2015 | 25 | 0.270 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2021 | 14 | 0.260 |
Why?
|
| Overweight | 2 | 2023 | 65 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 98 | 0.250 |
Why?
|
| Condoms | 4 | 2020 | 6 | 0.250 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 22 | 0.250 |
Why?
|
| RNA, Ribosomal, 16S | 6 | 2023 | 57 | 0.250 |
Why?
|
| Memory Disorders | 2 | 2017 | 177 | 0.250 |
Why?
|
| Socioeconomic Factors | 9 | 2020 | 329 | 0.250 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2022 | 8 | 0.250 |
Why?
|
| Osteocalcin | 2 | 2022 | 23 | 0.240 |
Why?
|
| Homosexuality, Female | 2 | 2014 | 4 | 0.240 |
Why?
|
| Bisexuality | 2 | 2014 | 7 | 0.240 |
Why?
|
| Obesity | 3 | 2023 | 289 | 0.240 |
Why?
|
| Anus Neoplasms | 2 | 2015 | 6 | 0.240 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2014 | 6 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2017 | 30 | 0.230 |
Why?
|
| Medically Unexplained Symptoms | 1 | 2023 | 1 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 79 | 0.230 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 49 | 0.230 |
Why?
|
| Incidence | 7 | 2016 | 759 | 0.220 |
Why?
|
| Hand Strength | 2 | 2021 | 60 | 0.220 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 506 | 0.220 |
Why?
|
| Aging | 4 | 2022 | 1630 | 0.220 |
Why?
|
| Kynurenine | 1 | 2022 | 3 | 0.210 |
Why?
|
| Ageusia | 1 | 2022 | 1 | 0.210 |
Why?
|
| Insulin Resistance | 2 | 2013 | 60 | 0.210 |
Why?
|
| Oxytocin | 1 | 2022 | 10 | 0.210 |
Why?
|
| Multivariate Analysis | 10 | 2015 | 332 | 0.210 |
Why?
|
| Periodontitis | 1 | 2022 | 4 | 0.200 |
Why?
|
| Wrist | 1 | 2022 | 17 | 0.200 |
Why?
|
| Emigrants and Immigrants | 2 | 2020 | 21 | 0.200 |
Why?
|
| Drug Prescriptions | 2 | 2022 | 35 | 0.200 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 221 | 0.200 |
Why?
|
| beta-Defensins | 1 | 2022 | 2 | 0.200 |
Why?
|
| Psychomotor Performance | 4 | 2017 | 220 | 0.200 |
Why?
|
| Leptin | 1 | 2022 | 23 | 0.200 |
Why?
|
| Exposure to Violence | 1 | 2022 | 6 | 0.200 |
Why?
|
| Actigraphy | 1 | 2022 | 98 | 0.200 |
Why?
|
| Temporal Lobe | 2 | 2020 | 109 | 0.200 |
Why?
|
| Oral Health | 2 | 2020 | 3 | 0.200 |
Why?
|
| Macrophage Activation | 1 | 2021 | 13 | 0.200 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 125 | 0.190 |
Why?
|
| Time Factors | 9 | 2020 | 1640 | 0.190 |
Why?
|
| Integrases | 1 | 2021 | 3 | 0.190 |
Why?
|
| Sex Characteristics | 1 | 2022 | 135 | 0.190 |
Why?
|
| Osteoporosis | 1 | 2022 | 84 | 0.190 |
Why?
|
| Premenopause | 1 | 2021 | 20 | 0.190 |
Why?
|
| Attention | 2 | 2019 | 145 | 0.190 |
Why?
|
| Shoulder Injuries | 1 | 2002 | 143 | 0.190 |
Why?
|
| Physical Abuse | 2 | 2020 | 4 | 0.190 |
Why?
|
| Memory, Short-Term | 3 | 2017 | 103 | 0.190 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 60 | 0.190 |
Why?
|
| Lactobacillus | 3 | 2016 | 20 | 0.190 |
Why?
|
| Monocytes | 1 | 2021 | 111 | 0.190 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2019 | 12 | 0.180 |
Why?
|
| Hepacivirus | 1 | 2021 | 75 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 16 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 1 | 2020 | 10 | 0.180 |
Why?
|
| Contraception | 2 | 2012 | 5 | 0.180 |
Why?
|
| Raltegravir Potassium | 4 | 2022 | 9 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2022 | 3325 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2020 | 26 | 0.170 |
Why?
|
| Frontal Lobe | 1 | 2020 | 85 | 0.170 |
Why?
|
| Knee Injuries | 1 | 2002 | 228 | 0.170 |
Why?
|
| Olive Oil | 1 | 2019 | 2 | 0.170 |
Why?
|
| Marijuana Smoking | 2 | 2012 | 5 | 0.170 |
Why?
|
| Child | 5 | 2021 | 1376 | 0.170 |
Why?
|
| Food Supply | 1 | 2019 | 14 | 0.170 |
Why?
|
| Prisoners | 1 | 2019 | 11 | 0.170 |
Why?
|
| Urban Population | 3 | 2016 | 143 | 0.170 |
Why?
|
| Alcoholism | 2 | 2017 | 83 | 0.160 |
Why?
|
| Perception | 2 | 2016 | 83 | 0.160 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 13 | 0.160 |
Why?
|
| Rectum | 1 | 2019 | 61 | 0.160 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2018 | 3 | 0.160 |
Why?
|
| Vaginal Douching | 1 | 2018 | 9 | 0.160 |
Why?
|
| Thigh | 1 | 2018 | 35 | 0.160 |
Why?
|
| Narration | 1 | 2018 | 12 | 0.160 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 143 | 0.160 |
Why?
|
| Peptide Hydrolases | 1 | 2018 | 15 | 0.160 |
Why?
|
| Injections, Intra-Articular | 1 | 2019 | 88 | 0.160 |
Why?
|
| Periodontal Attachment Loss | 1 | 2018 | 3 | 0.160 |
Why?
|
| Odds Ratio | 6 | 2022 | 286 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2018 | 19 | 0.150 |
Why?
|
| Interleukin-6 | 4 | 2022 | 109 | 0.150 |
Why?
|
| Acute Pain | 1 | 2018 | 21 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4930 | 0.150 |
Why?
|
| Naltrexone | 1 | 2017 | 3 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2017 | 14 | 0.150 |
Why?
|
| Crack Cocaine | 2 | 2014 | 4 | 0.150 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2022 | 25 | 0.150 |
Why?
|
| AIDS Dementia Complex | 1 | 2017 | 41 | 0.150 |
Why?
|
| Uterine Cervical Diseases | 2 | 2007 | 4 | 0.140 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 5 | 0.140 |
Why?
|
| Wound Healing | 1 | 2018 | 168 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 349 | 0.140 |
Why?
|
| Unsafe Sex | 3 | 2014 | 7 | 0.140 |
Why?
|
| Norepinephrine | 1 | 2016 | 21 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 147 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 1 | 2016 | 20 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 298 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 101 | 0.140 |
Why?
|
| Censuses | 1 | 2016 | 6 | 0.140 |
Why?
|
| Age Factors | 5 | 2020 | 852 | 0.130 |
Why?
|
| Coronary Disease | 1 | 2016 | 87 | 0.130 |
Why?
|
| Decision Making | 2 | 2020 | 227 | 0.130 |
Why?
|
| Self Efficacy | 1 | 2016 | 57 | 0.130 |
Why?
|
| Executive Function | 4 | 2020 | 124 | 0.130 |
Why?
|
| Reproductive Health | 1 | 2015 | 2 | 0.130 |
Why?
|
| Coercion | 1 | 2015 | 4 | 0.130 |
Why?
|
| Child Abuse, Sexual | 1 | 2015 | 12 | 0.130 |
Why?
|
| Sexuality | 1 | 2015 | 18 | 0.130 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 80 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 355 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 10 | 0.130 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 79 | 0.130 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2015 | 7 | 0.130 |
Why?
|
| Femur | 1 | 2018 | 393 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2015 | 30 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 82 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2014 | 46 | 0.120 |
Why?
|
| Glycogen | 1 | 2014 | 12 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2013 | 130 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2016 | 216 | 0.120 |
Why?
|
| Sexism | 1 | 2014 | 8 | 0.120 |
Why?
|
| Brain Injuries | 1 | 2015 | 48 | 0.120 |
Why?
|
| Body Composition | 2 | 2020 | 57 | 0.120 |
Why?
|
| Hospitalization | 1 | 2017 | 319 | 0.120 |
Why?
|
| Self Concept | 1 | 2014 | 46 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 74 | 0.120 |
Why?
|
| Spouse Abuse | 1 | 2014 | 5 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 1246 | 0.120 |
Why?
|
| Racism | 1 | 2014 | 32 | 0.110 |
Why?
|
| Vaginal Smears | 2 | 2011 | 17 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 298 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 9 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2013 | 22 | 0.110 |
Why?
|
| Educational Status | 4 | 2022 | 297 | 0.110 |
Why?
|
| Heroin Dependence | 1 | 2013 | 10 | 0.110 |
Why?
|
| Attitude to Health | 3 | 2009 | 98 | 0.110 |
Why?
|
| Baseball | 1 | 2015 | 107 | 0.110 |
Why?
|
| Models, Psychological | 1 | 2013 | 67 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2014 | 191 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 1 | 2013 | 18 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 137 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2022 | 223 | 0.110 |
Why?
|
| Tryptophan | 2 | 2023 | 15 | 0.110 |
Why?
|
| Vitamin D | 1 | 2013 | 32 | 0.110 |
Why?
|
| Contraceptive Agents, Female | 1 | 2012 | 1 | 0.110 |
Why?
|
| Contraceptive Devices, Female | 1 | 2012 | 1 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2020 | 520 | 0.110 |
Why?
|
| RNA | 2 | 2022 | 41 | 0.100 |
Why?
|
| Carotid Arteries | 2 | 2023 | 54 | 0.100 |
Why?
|
| Colposcopy | 1 | 2012 | 3 | 0.100 |
Why?
|
| Adiposity | 2 | 2023 | 47 | 0.100 |
Why?
|
| Vitamins | 1 | 2012 | 16 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2013 | 218 | 0.100 |
Why?
|
| Ascorbic Acid | 1 | 2012 | 33 | 0.100 |
Why?
|
| Garlic | 1 | 2012 | 3 | 0.100 |
Why?
|
| Mouth | 2 | 2014 | 12 | 0.100 |
Why?
|
| Polyneuropathies | 1 | 2011 | 3 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2012 | 15 | 0.100 |
Why?
|
| Oxazines | 2 | 2022 | 9 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2012 | 53 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2022 | 84 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 92 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2012 | 85 | 0.100 |
Why?
|
| Depression, Postpartum | 1 | 2011 | 16 | 0.100 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2012 | 58 | 0.100 |
Why?
|
| Benzoxazines | 2 | 2022 | 10 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 433 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 2005 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 346 | 0.090 |
Why?
|
| Receptors, Opioid, mu | 1 | 2010 | 6 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2010 | 20 | 0.090 |
Why?
|
| Drug Users | 1 | 2010 | 4 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2022 | 12 | 0.090 |
Why?
|
| Self Disclosure | 3 | 2020 | 9 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2022 | 48 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2010 | 2 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2022 | 69 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2018 | 3557 | 0.090 |
Why?
|
| Pregnancy | 4 | 2017 | 388 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2009 | 28 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 223 | 0.080 |
Why?
|
| Child Care | 1 | 2009 | 2 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 89 | 0.080 |
Why?
|
| Family Characteristics | 1 | 2009 | 20 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 1126 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2009 | 75 | 0.080 |
Why?
|
| Saliva | 2 | 2020 | 54 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 161 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2020 | 16 | 0.080 |
Why?
|
| Waist-Hip Ratio | 1 | 2008 | 16 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2020 | 27 | 0.080 |
Why?
|
| Intimate Partner Violence | 2 | 2020 | 16 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2020 | 50 | 0.080 |
Why?
|
| Disabled Persons | 1 | 2009 | 129 | 0.080 |
Why?
|
| Heterosexuality | 2 | 2020 | 3 | 0.080 |
Why?
|
| Trichomonas Infections | 1 | 2007 | 3 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2020 | 102 | 0.080 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2007 | 6 | 0.080 |
Why?
|
| Alphapapillomavirus | 1 | 2007 | 6 | 0.070 |
Why?
|
| Contraception Behavior | 1 | 2007 | 6 | 0.070 |
Why?
|
| Parenting | 1 | 2008 | 72 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2007 | 20 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 468 | 0.070 |
Why?
|
| Gait | 2 | 2021 | 406 | 0.070 |
Why?
|
| Physical Examination | 1 | 2007 | 117 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 398 | 0.070 |
Why?
|
| Dental Care for Chronically Ill | 1 | 2005 | 1 | 0.070 |
Why?
|
| Dental Care | 1 | 2005 | 3 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 73 | 0.060 |
Why?
|
| Demography | 2 | 2014 | 78 | 0.060 |
Why?
|
| Self Report | 2 | 2018 | 221 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2016 | 132 | 0.060 |
Why?
|
| Emtricitabine | 1 | 2023 | 4 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2005 | 331 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2023 | 82 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2023 | 39 | 0.060 |
Why?
|
| Obesity, Abdominal | 1 | 2023 | 22 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2014 | 298 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2003 | 14 | 0.050 |
Why?
|
| Social Support | 2 | 2018 | 186 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 6 | 0.050 |
Why?
|
| Genotype | 2 | 2014 | 399 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 7 | 0.050 |
Why?
|
| Arginine Vasopressin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Cough | 1 | 2022 | 12 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 17 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 38 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 43 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2022 | 10 | 0.050 |
Why?
|
| Lysophosphatidylcholines | 1 | 2022 | 7 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 93 | 0.050 |
Why?
|
| Social Perception | 1 | 2022 | 23 | 0.050 |
Why?
|
| Elafin | 1 | 2022 | 1 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2022 | 202 | 0.050 |
Why?
|
| DNA, Viral | 2 | 2016 | 98 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 129 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2013 | 32 | 0.050 |
Why?
|
| Polysomnography | 1 | 2022 | 94 | 0.050 |
Why?
|
| Transcriptome | 1 | 2022 | 84 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2022 | 61 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 11 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 159 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 42 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 323 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 140 | 0.050 |
Why?
|
| HIV Integrase | 1 | 2021 | 1 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 15 | 0.050 |
Why?
|
| Pyridones | 1 | 2021 | 14 | 0.050 |
Why?
|
| Quinolones | 1 | 2021 | 22 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2022 | 91 | 0.050 |
Why?
|
| Prevotella | 1 | 2021 | 2 | 0.050 |
Why?
|
| Adenine | 1 | 2021 | 4 | 0.050 |
Why?
|
| Tenofovir | 1 | 2021 | 4 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2021 | 22 | 0.050 |
Why?
|
| Shoulder | 1 | 2002 | 158 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 11 | 0.050 |
Why?
|
| Dentists | 1 | 2020 | 2 | 0.050 |
Why?
|
| Confidentiality | 1 | 2020 | 11 | 0.050 |
Why?
|
| Perimenopause | 1 | 2021 | 24 | 0.050 |
Why?
|
| Rape | 1 | 2020 | 7 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 129 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2021 | 74 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 18 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 4 | 0.050 |
Why?
|
| Latin America | 1 | 2020 | 6 | 0.050 |
Why?
|
| Africa | 1 | 2020 | 10 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2020 | 24 | 0.050 |
Why?
|
| Smokers | 1 | 2020 | 10 | 0.040 |
Why?
|
| Piperazines | 1 | 2021 | 93 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2020 | 34 | 0.040 |
Why?
|
| Speech Disorders | 1 | 2020 | 13 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2020 | 26 | 0.040 |
Why?
|
| Alkynes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Occupations | 1 | 2020 | 15 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 163 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2020 | 26 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 21 | 0.040 |
Why?
|
| Psychology | 1 | 2020 | 21 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 53 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 31 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 221 | 0.040 |
Why?
|
| Prisons | 1 | 2019 | 12 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 812 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 99 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2019 | 10 | 0.040 |
Why?
|
| Corynebacterium | 1 | 2019 | 5 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2018 | 6 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 532 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2018 | 1 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2018 | 41 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2019 | 64 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2018 | 22 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 32 | 0.040 |
Why?
|
| Mother-Child Relations | 2 | 2009 | 40 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 103 | 0.040 |
Why?
|
| Income | 1 | 2018 | 77 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 8 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 85 | 0.040 |
Why?
|
| New York City | 1 | 2017 | 18 | 0.040 |
Why?
|
| Mass Screening | 1 | 2018 | 180 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 351 | 0.040 |
Why?
|
| Pain Management | 1 | 2018 | 144 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 118 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 10 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 874 | 0.030 |
Why?
|
| Social Segregation | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 558 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 85 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 402 | 0.030 |
Why?
|
| Mental Recall | 1 | 2016 | 74 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 117 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 37 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 492 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 113 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 107 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 90 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 90 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 111 | 0.030 |
Why?
|
| Poverty | 1 | 2016 | 97 | 0.030 |
Why?
|
| Serotyping | 1 | 2014 | 12 | 0.030 |
Why?
|
| Metagenome | 1 | 2015 | 22 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 129 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 53 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 24 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 258 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 199 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 132 | 0.030 |
Why?
|
| Speech Perception | 1 | 2015 | 48 | 0.030 |
Why?
|
| Gender Identity | 1 | 2014 | 21 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 216 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 131 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 14 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 216 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2014 | 17 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 149 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 105 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 44 | 0.030 |
Why?
|
| Gene Expression | 1 | 2014 | 231 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 105 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2013 | 72 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 14 | 0.030 |
Why?
|
| Heroin | 1 | 2013 | 3 | 0.030 |
Why?
|
| Reading | 1 | 2013 | 40 | 0.030 |
Why?
|
| San Francisco | 1 | 2013 | 3 | 0.030 |
Why?
|
| Learning | 1 | 2013 | 80 | 0.030 |
Why?
|
| Biopsy | 1 | 2013 | 239 | 0.030 |
Why?
|
| Insulin | 1 | 2013 | 92 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2013 | 112 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2013 | 136 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2011 | 159 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 400 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2011 | 42 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 54 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 201 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 25 | 0.020 |
Why?
|
| Patient Participation | 1 | 2009 | 51 | 0.020 |
Why?
|
| Health Personnel | 1 | 2009 | 115 | 0.020 |
Why?
|
| Anthropometry | 1 | 2008 | 38 | 0.020 |
Why?
|
| Papanicolaou Test | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 2007 | 14 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 20 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 232 | 0.020 |
Why?
|
| Safe Sex | 1 | 2007 | 1 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 325 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 10 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 96 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 11 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 654 | 0.020 |
Why?
|
| Dental Anxiety | 1 | 2005 | 2 | 0.020 |
Why?
|
| Unemployment | 1 | 2005 | 3 | 0.020 |
Why?
|
| California | 1 | 2005 | 31 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 54 | 0.020 |
Why?
|
| Marital Status | 1 | 2004 | 15 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 77 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 103 | 0.020 |
Why?
|
| Life Style | 1 | 2004 | 212 | 0.010 |
Why?
|